NCT00607919

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 209 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 10 Years – 16 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)

Conditions

• Attention Deficit Hyperactivity Disorder
• Dyslexia

Interventions

Type	Name	Description
DRUG	Atomoxetine	Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
DRUG	Placebo	oral, daily, for 16 weeks

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-11-01
• Completion: 2011-02-01
• First posted: 2008-02-06
• Last updated: 2011-12-15
• Results posted: 2011-12-15

Locations

16 sites across 1 country: United States